Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest & Investment Income (2016 - 2025)

Zevra Therapeutics' Interest & Investment Income history spans 11 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 2445.21% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $6.9 million, up 219.36%, while the annual FY2025 figure was $6.9 million, 219.36% up from the prior year.
  • Interest & Investment Income reached $1.7 million in Q4 2025 per ZVRA's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.4 million in Q2 2025 to a low of -$73000.0 in Q4 2024.
  • Average Interest & Investment Income over 5 years is $820000.0, with a median of $736000.0 recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: soared 12533.33% in 2022, then crashed 134.76% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $125000.0 in 2021, then skyrocketed by 724.8% to $1.0 million in 2022, then tumbled by 79.63% to $210000.0 in 2023, then plummeted by 134.76% to -$73000.0 in 2024, then soared by 2445.21% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Interest & Investment Income are $1.7 million (Q4 2025), $2.3 million (Q3 2025), and $2.4 million (Q2 2025).